High-throughput biologics screening

Potential drug targets arising from the explosion in proteomics research have increased in tandem with high-throughput biologics synthesis. 

Traditional methods such as enzyme-linked immunosorbent assays (ELISA) are labour-intensive and require large sample volumes, whereas mass spectrometry-based technologies can lack sensitivity and may yield variable results.  Whilst both are useful tools in their own right, critical success factors for drug discoverers dictate that screening methods should be cost-effective, highly multiplex and fast.

In response to demands for high-throughput biologics screening, Arrayjet has developed a novel assay that is:

  • more sensitive than ELISA
  • simpler than mass spectrometry
  • Higher throughput than cellular-based assays